Press Releases Search View

Select Category

Recent News

Search By:

Search By Release Date

67 Record(s) Found. Displaying Page 1:

1 2 3 4 [Next >>]

Fifteen Students Launch Into Space Research Internship

Release Date: 1-Jul-08 Author or Contact: Kathy Major
July 1, 2008 -- Fifteen students are spending the summer at NASA Johnson Space Center, working alongside space life scientists and space medicine researchers as part of the National Space Biomedical Research Institute’s Summer Internship Program. As the International Space Station nears completion, these young scientists are getting a taste of health and medical research related to living in space for long periods and to sending humans back... More on Fifteen Students Launch Into Space...
Click to read Fifteen Students Launch Into Space Research Internship

Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe

Release Date: 30-Jun-08 Author or Contact: Channing Burke
June 30, 2008--Introgen Therapeutics, Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting marketing approval for ADVEXIN(R) p53 therapy to treat recurrent, refractory head and neck cancer. Simultaneously, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application (MAA) to the European Medicines Evaluation Agency (EMEA) for the same indication.... More on Introgen Submits ADVEXIN(R) Regulatory...
Click to read Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe

Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal® as Compared to Topical Testim® Examining Effects on Male Fertility and Testicular Function

Release Date: 30-Jun-08 Author or Contact: Joseph Podolski
June 30, 2008 -- Repros Therapeutics Inc. reported today that the clinical sites have been initiated for its Phase 2b clinical study monitoring the effects of Repros’ oral drug Androxal® on male fertility and testicular function in patients being treated for low testosterone as compared to Testim®, a popular marketed topical testosterone medication. Enrollment of the 24 patients will commence at two sites in the New York City area shortly. The... More on Repros Therapeutics Inc. Initiates a...
Click to read Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal® as Compared to Topical Testim® Examining Effects on Male Fertility and Testicular Function

Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting

Release Date: 16-Jun-08 Author or Contact: Linda Hohlfeld
June 16, 2008 -- Opexa Therapeutics, Inc., a cell therapy development and commercialization company, today announced a recent poster presentation at the 2008 Annual Meeting of the International Society for Stem Cell Research held in Philadelphia June 11 – 14, 2008. The poster, titled “Ex vivo differentiation of adult human peripheral blood monocyte-derived cells into functional insulin-producing cells for the treatment of diabetes” was presented... More on Opexa Therapeutics Presents...
Click to read Opexa Therapeutics Presents Monocyte-Derived Islet Cell Research at the International Society for Stem Cell Research Annual Meeting

PLx Pharma Demonstrates Bioequivalence with aspirin and PL 2100 ~ Aspirin-PC

Release Date: 16-Jun-08 Author or Contact: Ron Zimmerman
June 16, 2008 -- PLx Pharma Inc. announced today that it has successfully completed a clinical trial of PL 2100, also known as Aspirin-PC and demonstrated it’s bioequivalence with regular aspirin. This trial demonstrates PL 2100 Aspirin-PC may bridge to the safety and efficacy of aspirin for prescription (Rx) treatment and prevention of secondary prevention of stroke and myocardial infarction and over-the-counter (OTC) analgesic and fever... More on PLx Pharma Demonstrates Bioequivalence...
Click to read PLx Pharma Demonstrates Bioequivalence with aspirin and PL 2100 ~ Aspirin-PC

Monebo and Freescale Partner to Deliver Innovative Heart Monitoring Platform

Release Date: 16-Jun-08 Author or Contact:
June 16, 2008 – Freescale Semiconductor and Monebo Technologies announced a partnership to deliver a comprehensive platform solution for medical equipment using electrocardiogram (ECG) technology. The “ECG-on-a-chip” solution combines Monebo’s Kinetic™ ECG software with Freescale’s embedded processing technology to enable medical equipment manufacturers to develop easy-to-use ECG monitoring tools. According to the World Health Organization,... More on Monebo and Freescale Partner to Deliver...
Click to read Monebo and Freescale Partner to Deliver Innovative Heart Monitoring Platform

LDR Announces Release of its ROI-A™ Anterior Lumbar Partial Vertebral Body Replacement Device

Release Date: 16-Jun-08 Author or Contact: James Burrows
June 16, 2008 -- LDR, a total spine solution company, announced today that it has begun to market its ROI-A™ partial vertebral body replacement device following 510(k) clearance from the United States Food and Drug Administration in April. The ROI-A™ system incorporates the innovative verteBRIDGE™ anchoring technology. The ROI-A™ is a stand-alone implant system with zero profile, self-locking anchoring plates designed for initial and long-term... More on LDR Announces Release of its ROI-A™...
Click to read LDR Announces Release of its ROI-A™ Anterior Lumbar Partial Vertebral Body Replacement Device

Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin® for Multiple Sclerosis

Release Date: 12-Jun-08 Author or Contact: Lynne Hohlfeld
June 12, 2008 -- Opexa Therapeutics, Inc., a cell therapy development and commercialization company, today announced favorable safety and efficacy data for Tovaxin®, the Company’s investigational T-cell vaccination therapy for multiple sclerosis (MS), in the second year of open-label clinical retreatment studies in patients with MS. The “intent to treat” population of 22 patients included 13 with relapsing remitting multiple sclerosis (RRMS)... More on Opexa Therapeutics Reports Favorable...
Click to read Opexa Therapeutics Reports Favorable Two-Year Data in Phase I/II Retreatment Studies of Tovaxin® for Multiple Sclerosis

Texas' Emerging Technology Fund Electrifies the Texas Economy

Release Date: 12-Jun-08 Author or Contact: Craig Casselberry
June 12, 2008 -- The Texas Emerging Technology Fund (TETF) was created by the Texas Legislature at the urging of Governor Rick Perry in 2005 and reauthorized in 2007. The TETF provides up and coming Texas technologies with the support needed to develop and commercialize new technologies, many of which have ties to universities. To date, the TETF has allocated $127.5 million dollars to Texas companies and partnering universities creating a deal... More on Texas' Emerging Technology Fund...
Click to read Texas' Emerging Technology Fund Electrifies the Texas Economy

Kinetic Concept's V.A.C.(R) Therapy Recommendations for Six Wound Types Published

Release Date: 11-Jun-08 Author or Contact: Kristie Madara
June 11, 2008 -- The first comprehensive publication of international best practices for the use of KCI’s V.A.C.® Therapy was introduced last week at the 3rd Congress of the World Union of Wound Healing Societies (WUWHS) in Toronto, Canada. The consensus document, Principles of Best Practice - Vacuum Assisted Closure: Recommendations for Use, A Consensus Document, was developed by an international expert working group to provide guidance on the... More on Kinetic Concept's V.A.C.(R) Therapy...
Click to read Kinetic Concept's V.A.C.(R) Therapy Recommendations for Six Wound Types Published

Introgen Creates Technical Services Company and Announces Strategic Alliance with Texas A&M University System to Expand GMP Manufacturing Programs

Release Date: 11-Jun-08 Author or Contact: C. Channing Burke
June 11, 2008--Today, Introgen Therapeutics, Inc. announced the formation of Introgen Technical Services, Inc. ("ITS") to pursue contract production, process development and manufacturing services. It is anticipated that ITS will supply Introgen's future product inventory needs for development stage and future commercial products. Advances in both scale and flexibility of biologics production have allowed Introgen to build its product... More on Introgen Creates Technical Services...
Click to read Introgen Creates Technical Services Company and Announces Strategic Alliance with Texas A&M University System to Expand GMP Manufacturing Programs

ApoCell, Reata kick off clinical trial of diabetic renal disease drug

Release Date: 10-Jun-08 Author or Contact: Monica Perin
ApoCell Inc. and Reata Pharmaceuticals Inc. have begun work on a phase II clinical trial of Reata RTA 402 for the treatment of diabetic renal disease. RTA 402 is the lead molecule emerging from Reata's platform of Antioxidant Inflammation Modulators (AIMs). RTA 402 has also shown promising activity in a recent cancer phase I study of patients with advanced solid tumors. Houston-based ApoCell develops assays for biomarker expression in... More on ApoCell, Reata kick off clinical trial...
Click to read ApoCell, Reata kick off clinical trial of diabetic renal disease drug

Texas A&M System and Introgen Agree to Joint Biopharmaceutical Manufacturing Compact

Release Date: 10-Jun-08 Author or Contact: Frank Giffis
June 10, 2008 -- The Texas A&M University System, Austin-based Introgen Therapeutics, Inc. and its wholly owned spinout Introgen Technical Services, Inc. (ITS) today announced formation of a far-reaching alliance to develop and produce therapeutics, vaccines and delivery systems for human and veterinary applications. The alliance will work with the biopharmaceutical industry, academic researchers and government clients, including the biodefense... More on Texas A&M System and Introgen Agree to...
Click to read Texas A&M System and Introgen Agree to Joint Biopharmaceutical Manufacturing Compact

Repros Therapeutics Inc. Announces That Initial Findings for Proellex(R) Show No Gross Cancer Tumors in First Completed Animal Carcinogenicity Study

Release Date: 9-Jun-08 Author or Contact: Joseph Podolski
June 9 -- Repros Therapeutics Inc. today released initial findings from evaluation of gross necropsies conducted upon completion of the in-life portion of a six-month mouse study conducted to satisfy a portion of the FDA mandated two-species trials to demonstrate the lack of carcinogenic potential for new chemical entities. In the positive and negative controlled study, Proellex showed no gross potential for tumor induction as compared to both... More on Repros Therapeutics Inc. Announces That...
Click to read Repros Therapeutics Inc. Announces That Initial Findings for Proellex(R) Show No Gross Cancer Tumors in First Completed Animal Carcinogenicity Study

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

Release Date: 4-Jun-08 Author or Contact: Stephen B. Thompson
June 4, 2008 -- Access Pharmaceuticals, Inc. and Jiangsu Aosaikang Pharmaceutical Co., LTD., a premier pharmaceutical company focused on bringing oncology medicines to the China market, today announced the signing of a definitive licensing agreement under which ASK will manufacture, develop and commercialize Access' proprietary product ProLindac(TM) for the Greater China Region which includes the People's Republic of China, the Hong Kong Special... More on Access Licenses ProLindac(TM) to...
Click to read Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA

Release Date: 3-Jun-08 Author or Contact: Bobbie Faulkner
June 3, 2008 – Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received Fast Track status from the U.S. Food and Drug Administration (FDA) for development of LX1032, an orally-delivered small molecule drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is one of four programs in... More on Lexicon's Drug Candidate for Carcinoid...
Click to read Lexicon's Drug Candidate for Carcinoid Syndrome Receives Fast Track Status From the FDA

BioMedical Enterprises, Inc. Announces U.S. Launch of the OSSAnchor™ Grip Nitinol Soft Tissue Anchor

Release Date: 2-Jun-08 Author or Contact: Eric Marcano
June 2, 2008 – BioMedical Enterprises, Inc., a privately held medical device company and leader in orthopaedic shape memory implant technology, today announced the launch of the OSSAnchor™ Grip, a nitinol implant designed to approximate soft tissue to bone. The Grip is the first in the family of OSSAnchor™ nitinol soft tissue implants, designed to secure soft tissue to bone. The Grip is a nitinol implant with aggressive barbs on the legs... More on BioMedical Enterprises, Inc. Announces...
Click to read BioMedical Enterprises, Inc. Announces U.S. Launch of the OSSAnchor™ Grip Nitinol Soft Tissue Anchor

Reata Pharmaceuticals Announces First-In-Man Study of RTA 402 Yields Promising Results

Release Date: 1-Jun-08 Author or Contact: Kathryn Morris
June 1, 2008 -- Reata Pharmaceuticals, Inc. announced results from a first-in-man study of RTA 402 in patients with advanced cancers, presented in an oral session at the annual meeting of the American Society for Clinical Oncology. RTA 402 is the clinical lead from Reata’s Antioxidant Inflammation Modulators (AIMs), a new and highly promising category of drugs for the treatment of cancer and inflammation. One of the study’s Principal... More on Reata Pharmaceuticals Announces...
Click to read Reata Pharmaceuticals Announces First-In-Man Study of RTA 402 Yields Promising Results

Repros Therapeutics Inc. Announces That Initial Findings for Proellex® Show No Adverse Effects on the Endometrium after One Year on Drug

Release Date: 29-May-08 Author or Contact: Joseph S. Podolski
May 29, 2008 -- Repros Therapeutics Inc. today released encouraging results from its one-year extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no findings of abnormal endometrial biopsies post menses after cessation of administration of drug. Repros has described in previous communications that it had developed a unique approach to dosing with Proellex which... More on Repros Therapeutics Inc. Announces That...
Click to read Repros Therapeutics Inc. Announces That Initial Findings for Proellex® Show No Adverse Effects on the Endometrium after One Year on Drug

ArthroCare to Receive 2008 Frost & Sullivan Product Innovation Award

Release Date: 29-May-08 Author or Contact: Kellie Reagan
May 29, 2008 -- ArthroCare(R) Corp. announced today that its Opus(R) TwinLock(TM) Knotless Fixation System, launched last year, has earned them the 2008 Frost & Sullivan Award for Product Innovation. The Award is presented each year to the company that has demonstrated excellence in new products and technologies within their industry. To identify the recipient of the Award, Frost & Sullivan does not accept nominations or submissions. All... More on ArthroCare to Receive 2008 Frost &...
Click to read ArthroCare to Receive 2008 Frost & Sullivan Product Innovation Award

1 2 3 4 [Next >>]

Contact Us | Site Map |

| OPML | Search This Site | Home
Schipul Web Design | Tendenci® Content Management Software | Privacy | Terms and Conditions